The FDA has issued the Actos warnings related to cancer in September 2010. They were reviewing the data from an ongoing ten year epidemiological study. It was especially designed to determine whether an Actos might increase the risk of bladder cancer. FDA already possesses information warning patients that longest exposure along with highest dosage has increased chances of having bladder cancer. France also had its epidemiological study that worked synonymously with the review of FDA. The review of FDA was that Actos was associated with an increased risk of bladder cancer. Other actos warnings advising healthcare professionals are not to use Actos in patients with active bladder cancer. The other warning was to use Actos with caution in patients, who have a history of bladder cancer. The agency issued other Actos warnings. The most serious is warning of 2007 about the risk of congestive heart failure. The agency even placed a black box warning on the label to enhance the visibility as well as to increase the awareness among patients.
(Sponsored attorney advertising)